VIDEO: Alimera’s CEO views sustained therapies as path forward

CHICAGO — Dan Myers, CEO of Alimera Sciences, talks about the work being done in sustained release treatment for neovascular age-related macular degeneration and diabetic macular edema, as well as other retina diseases. Alimera's sustained release fluocinolone acetonide implant Iluvien has the potential to reduce patient burden of treatment compared with anti-VEGFs, which puts Alimera "on the right side of the issue as it relates to how we treat retina disease going forward," Myers said.